During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.
Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma
During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.
During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.